- Home
- BYAH vs ALZN Comparison
BYAH vs ALZN Comparison
Compare BYAH & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYAH
- ALZN
- Stock Information
- Founded
- BYAH 2016
- ALZN 2016
- Country
- BYAH China
- ALZN United States
- Employees
- BYAH N/A
- ALZN N/A
- Industry
- BYAH Package Goods/Cosmetics
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- BYAH Consumer Discretionary
- ALZN Health Care
- Exchange
- BYAH Nasdaq
- ALZN Nasdaq
- Market Cap
- BYAH 9.8M
- ALZN 9.0M
- IPO Year
- BYAH 2024
- ALZN 2021
- Fundamental
- Price
- BYAH $0.34
- ALZN $2.54
- Analyst Decision
- BYAH
- ALZN Strong Buy
- Analyst Count
- BYAH 0
- ALZN 1
- Target Price
- BYAH N/A
- ALZN $42.00
- AVG Volume (30 Days)
- BYAH 343.5K
- ALZN 138.1K
- Earning Date
- BYAH 02-24-2026
- ALZN 12-11-2025
- Dividend Yield
- BYAH N/A
- ALZN N/A
- EPS Growth
- BYAH N/A
- ALZN N/A
- EPS
- BYAH N/A
- ALZN N/A
- Revenue
- BYAH $2,768,120.00
- ALZN N/A
- Revenue This Year
- BYAH N/A
- ALZN N/A
- Revenue Next Year
- BYAH N/A
- ALZN N/A
- P/E Ratio
- BYAH N/A
- ALZN N/A
- Revenue Growth
- BYAH 42.65
- ALZN N/A
- 52 Week Low
- BYAH $0.33
- ALZN $2.06
- 52 Week High
- BYAH $41.49
- ALZN $15.21
- Technical
- Relative Strength Index (RSI)
- BYAH N/A
- ALZN 54.71
- Support Level
- BYAH N/A
- ALZN $2.32
- Resistance Level
- BYAH N/A
- ALZN $2.68
- Average True Range (ATR)
- BYAH 0.00
- ALZN 0.18
- MACD
- BYAH 0.00
- ALZN 0.02
- Stochastic Oscillator
- BYAH 0.00
- ALZN 65.08
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.